Acute priapism associated with the use of sildenafil in a patient with sickle cell trait.

1. Sloand EM, Maciejewski JP, Dunn D, et al. Correction of the PNH defect by GPI-anchored protein transfer. Blood. 1998;92:4439-4445. 2. Civenni G, Test ST, Brodbeck U, Bütikofer P. In vitro incorporation of GPIanchored proteins into human erythrocytes and their fate in the membrane. Blood. 1998;91:1784-1792. 3. Hatanaka M, Seya T, Miyagawa S, et al. Cellular distribution of a GPIanchored complement regulatory protein CD59: homodimerization on the surface of HeLa and CD59-transfected CHO cells. J Biochem (Tokyo). 1998;123: 579-586. 4. Nickells MW, Alvarez JI, Lublin DM, Atkinson JP. Characterization of DAF-2, a high molecular weight form of decay-accelerating factor (DAF; CD55), as a covalently cross-linked dimer of DAF-1. J. Immunol. 1994;152:676-685. 5. Seya T, Farries T, Nickells M, Atkinson JP. Additional forms of human decayaccelerating factor (DAF). J. Immunol. 1987;139:1260-1267. 6. Davitz MA, Low MG, Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of complement regulatory protein. J. Exp. Med. 1986;163:1150-1161. 7. Holguin MH, Wilcox LA, Bernshaw NJ, Rosse WF, Parker CJ. Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein. Blood 1990;75: 284-289.